Table 2 Adjuvant therapy after surgical resection

Adjuvant therapy, n (%)

-

    Pembrolizumab

222 (54.8)

62 (48.4)

160 (57.8)

222 (61.7)

0 (0.0)

-

    Nivolumab

138 (34.1)

50 (39.1)

88 (31.8)

138 (38.3)

0 (0.0)

-

    Dabrafenib

45 (11.1)

16 (12.5)

29 (10.5)

0 (0.0)

45 (100.0)

-

    Trametinib

45 (11.1)

16 (12.5)

29 (10.5)

0 (0.0)

45 (100.0)

0.41

Time from resection to treatment initiation (days) (N = 350)^a, mean ± SD [median]

36.9 ± 32.5

[30.0]

33.1 ± 27.0

[28.0]

38.6 ± 34.6

[30.0]

0.15

37.7 ± 33.9

[30.0]

29.7 ± 16.3

[27.0]

1.00

 Patients who discontinued treatment (N = 329), n (%)^a

258 (78.4)

82 (80.4)

176 (77.5)

0.66

231 (78.3)

27 (79.4)

0.98

 Duration of AT (days) (N = 258)^a, mean ± SD [median]

327.8 ± 138.5

[357.0]

332.8 ± 141.0

[357.0]

325.6 ± 137.6

[355.0]

0.58

328.0 ± 141.6

[357.0]

326.1 ± 110.5

[357.0]

1.00

 Patients with changes in adjuvant treatment, n (%)

25 (6.2)

5 (3.9)

20 (7.2)

0.29

23 (6.4)

2 (4.4)